z-logo
Premium
C‐ MYC and IGF‐II mRNA‐binding protein (CRD‐BP/IMP‐1) in benign and malignant mesenchymal tumors
Author(s) -
Ioannidis Panayotis,
Trangas Theoni,
Dimitriadis Euthymios,
Samiotaki Martina,
Kyriazoglou Ioannis,
Tsiapalis Chris M.,
Kittas Christos,
Agnantis Niki,
Nielsen Finn Cilius,
Nielsen Jacob,
Christiansen Jan,
Pandis Nikos
Publication year - 2001
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.1512
Subject(s) - messenger rna , mesenchymal stem cell , biology , microbiology and biotechnology , cell culture , cancer research , gene , genetics
Mouse coding region determinant–binding (mCRD‐BP) and human IGF‐II mRNA–binding 1 (hIMP‐1) proteins are orthologous mRNA‐binding proteins that recognize c‐ myc and IGF‐II mRNA, respectively, and regulate their expression posttranscriptionally. Here, we confirm that human CRD‐BP/IMP‐1 binds to c‐ myc mRNA and that it is predominantly expressed in fetal tissues. Moreover, hCRD‐BP/IMP‐1 expression was detected in cell lines of neoplastic origin and in selected primary tumors. In a series of 33 malignant and 10 benign mesenchymal tumors, 73% and 40%, respectively, were found to express hCRD‐BP/IMP‐1. In particular, expression was significant in 14 Ewing's sarcomas, all of which were positive. The data suggest that hCRD‐BP/IMP‐1 plays a role in abnormal cell proliferation in mesenchymal tumors. © 2001 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom